Economics of Chronic Rhinosinusitis
Purpose of Review
The objective of this article is to provide an updated review of the economic burden of chronic rhinosinusitis (CRS) and discuss how both medical and surgical interventions impact direct and indirect costs related to CRS. By understanding the economics of CRS, clinicians may improve the patient-centeredness of their care and help distinguish between low and high value interventions.
Direct costs related to CRS are primarily driven by outpatient physician visits, prescription medical therapy, and endoscopic sinus surgery (ESS). CRS produces large indirect costs and these costs often vary based on the severity of the patients CRS-specific QoL impairment. The overall direct cost related to CRS is estimated to range between $10 and $13 billion per year in the USA. The overall indirect cost related to CRS-related losses in work productivity is estimated to be in excess of $20 billion per year.
In the appropriate patients with refractory CRS, ESS provides significant reductions in both direct and indirect costs; however, continued medical therapy alone may be a high value intervention in select patients who have lower severity in their baseline QoL and work productivity.
KeywordsChronic sinusitis Rhinosinusitis Pharmacoeconomics Cost Economic Burden of disease Value of care
Compliance with Ethical Standards
Conflict of Interest
Dr. Rudmik declares no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Scientific advisory board for BioInspire and 480 Biomedical.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.•• Rudmik L, Soler ZM. Medical therapies for adult chronic sinusitis: a systematic review. JAMA. 2015;314:926–39. Robust systematic review outlining the literature on various forms of medical therapy for CRS and provides a helpful evidence-based approach to managing CRS. CrossRefPubMedGoogle Scholar
- 14.Hirsch SD, Reiter ER, DiNardo LJ, Wan W, Schuman TA. Elimination of pain improves specificity of clinical diagnostic criteria for adult chronic rhinosinusitis. The Laryngoscope 2017.Google Scholar
- 22.Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for U.S. adults: national health interview survey, 2012. Vital and health statistics Series 10, Data from the National Health Survey 2014:1–161.Google Scholar
- 31.• Caulley L, Thavorn K, Rudmik L, Cameron C, Kilty SJ. Direct costs of adult chronic rhinosinusitis by using 4 methods of estimation: results of the US medical expenditure panel survey. J Allergy Clin Immunol. 2015;136:1517–22. Using four different methods of cost estimation, the overall annual direct cost of CRS in the US ranged between $4.5 and $12.5 billion. CrossRefPubMedGoogle Scholar
- 36.Patel ZM, Thamboo A, Rudmik L, Nayak JV, Smith TL, Hwang PH. Surgical therapy vs continued medical therapy for medically refractory chronic rhinosinusitis: a systematic review and meta-analysis. International forum of allergy & rhinology 2016.Google Scholar
- 42.Chatterjee S, Laxminarayan R. Costs of surgical procedures in Indian hospitals. BMJ open 2013; 3.Google Scholar
- 48.Bhattacharyya N. Contemporary assessment of the disease burden of sinusitis. American journal of rhinology & allergy. 2009;23:392–5.Google Scholar
- 50.• Rudmik L, Smith TL, Schlosser RJ, Hwang PH, Mace JC, Soler ZM. Productivity costs in patients with refractory chronic rhinosinusitis. Laryngoscope. 2014b;124:2007–12. Patients with refractory CRS who choose to undergo sinus surgery had a mean indirect cost of approximately $10,000 per year. Indirect costs were associated with the degree of quality of life impairment. CrossRefPubMedPubMedCentralGoogle Scholar
- 58.•• Rudmik L, Soler ZM, Hopkins C, et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Rhinology. 2016a;54:117–28. To optimize the value of care, patients with uncomplicated CRS who receive sinus sugery should have a minimum degree of quality of life impairment (SNOT-22 >20), fail a defined trial of appropriate medical therapy, and have objective evidence of inflammation on CT imaging. PubMedGoogle Scholar
- 69.Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131:1479–90.CrossRefPubMedPubMedCentralGoogle Scholar
- 73.• Rudmik L, Drummond M. Health economic evaluation: important principles and methodology. Laryngoscope. 2013;123:1341–7. Discusses important topics such as the various types of economic evaluation, the QALY, incremental cost effectiveness ratio, discounting, and handling of uncertainty. Good resource for clinicians interested in learning more about health economic evaluations. CrossRefPubMedGoogle Scholar